Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Oncogene|June 9, 2016
Targeting 6-phosphogluconate dehydrogenase in the oxidative PPP sensitizes leukemia cells to antimalarial agent dihydroartemisininS Elf, R Lin, S Xia, et al.
Bone Marrow Transplantation|November 26, 2013
Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantationC O Freytes, D H Vesole, J LeRademacher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 17, 2008
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE studyA Goy, S H Bernstein, B S Kahl, et al.
Leukemia|June 24, 2017
Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myelomaA Laganà, D Perumal, D Melnekoff, et al.
Leukemia|September 20, 2017
14-3-3ζ binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitorsY Gu, K Xu, C Torre, et al.
Bone Marrow Transplantation|September 28, 2011
Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myelomaO Ringdén, S Shrestha, G T da Silva, et al.
Leukemia|September 16, 2018
Correction: Pomalidomide, bortezomib, and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myelomaP G Richardson, C C Hofmeister, N S Raje, et al.
Leukemia|June 24, 2017
Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myelomaP G Richardson, C C Hofmeister, N S Raje, et al.
Leukemia|January 18, 2008
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 studyJ F San-Miguel, P G Richardson, P Sonneveld, et al.
Leukemia|May 15, 2013
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 studyA J Jakubowiak, D S Siegel, T Martin, et al.
Pageof 4